Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma - A randomized multicenter study

Blood

Volumn 87, Issue 7, 1996, Pages 2675-2682

  Österborg, Anders ^a   Boogaerts, Marc A ^b   Cimino, Renato ^b   Essers, Ursula ^b   Holowiecki, Jerzy ^b   Juliusson, Gunnar ^b   Jäger, Gerald ^b   Najman, Albert ^b   Peest, Dietrich ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TRANSFUSION; BONE PAIN; CANCER PATIENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HEMATOLOGICAL PARAMETERS; HUMAN; INFECTIOUS COMPLICATION; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SKIN TOXICITY; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTE COUNT; TREATMENT OUTCOME;

EID: 0030012115     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v87.7.2675.bloodjournal8772675     Document Type: Article

References (31)

1. Johnson RA, Roodman GD: Hematologic manifestations of malignancy. Dis Mon 35:721, 1989
2. Lee G: The anemia of chronic disease. Semin Hematol 20:61, 1983
3. Miller CB, Jones RJ, Piantadosi S, Abeloff MD, Spivak JL: Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med 322:1689, 1990
4. Eschbach JW, Kelly MR, Haley NR, Abels RI, Adamson JW: Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. N Engl J Med 321:158, 1989
5. Abels RI: Use of recombinant human erythropoietin in the treatment of anemia in patients who have cancer. Semin Oncol 19:29, 1992
6. Spivak JL: The application of recombinant erythropoietin in anemic patients with cancer. Semin Oncol 19:25, 1992
7. Ludwig H, Fritz E, Kotzmann H, Höcker P, Gisslinger H, Barnas U: Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med 322:1693, 1990
8. Oster W, Herrman F, Gamm H, Zeile G, Lindemann A, Müller G, Brune T, Kraemer HP, Mertelsmann R: Erythropoietin for the treatment of anemia of malignancy associated with neoplastic bone marrow infiltration. J Clin Oncol 8:956, 1990
9. Gerard-Marchant R, Hamlin I, Lennert K, Rilke F, Stansfeld AG, van Unnik JAM: Classification of non-Hodgkin's lymphomas. Lancet 2:406, 1974
10. Dune BGM, Salmon SE: A clinical staging system for multiple myeloma. Cancer 36:842, 1975
11. Carbone PP, Kaplan HS, Mushoff K, Smithers DW, Tubiana M: Report of the committee on Hodgkin's disease staging classification. Cancer Res 311:860, 1971
12. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN: Clinical staging of chronic lymphocytic leukemia. Blood 46:219, 1975
13. Beguin Y, Yerna M, Loo M, Weber M, Fillet G: Erythropoiesis in multiple myeloma: Defective red cell production due to inappropriate erythropoietin production. Br J Haematol 82:648, 1992
14. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG: Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 35:1, 1977
15. Cox DR: Regression models and life tables. J Roy Stat Soc 34:178, 1972
16. Cazzola M, Ponchio L, Beguin Y, Rosti V, Bergamaschi G, Liberate NL, Fregoni V, Nalli G, Barosi G, Ascari E: Subcutaneous erythropoietin for treatment of refractory anemia in hematologic disorders. Results of a phase I/II clinical trial. Blood 79:29, 1992
17. Barlogie B, Beck T: Recombinant human erythropoietin and the anemia of multiple myeloma. Stem Cells 11:88, 1993
18. Isnard F, Najman A, Jaar B, Fenaux P, Baillou C, Khoury E, Labopin M, Laporte JP, Woler M, Gorin NC, Bauters F: Efficacy of recombinant human erythropoietin in the treatment of refractory anemias without excess of blasts in myelodysplastic syndromes. Leuk Lymphoma 12:307, 1994
19. Majumdar G, Westwood NB, Bell-Witter C, Muggleston D, Phillips J, Pearson TC: Serum erythropoietin and circulating BFU-E in patients with multiple myeloma and anaemia but without renal failure. Leuk Lymphoma 9:173, 1993
20. Aoki I, Nishijima K, Homori M, Nakahara K, Higashi K, Ishikawa K: Responsiveness of bone marrow erythroid progenitors (CFU-E and BFU-E) to recombinant human erythropoietin (rh-Ep) in vitro in multiple myeloma. Br J Haematol 81:463, 1992
21. Link H, Boogaerts MA, Fauser AA, Slavin S, Reiffers J, Gorin NC, Carella AM, Mandelli F, Burdach S, Ferrant A, Linkesh W, Tura S, Bacigalupo A, Schindel F, Heinrich H: A controlled trial of recombinant human erythropoietin after bone marrow transplantation. Blood 84:3327, 1994
22. Chao NJ, Schriber JR, Long GD, Negrin RS, Catolico M, Brown BW, Miller LL, Blume KG: A randomized study of erythropoietin and granulocyte colony-stimulating factor (G-CSF) versus placebo and G-CSF for patients with Hodgkin's and non-Hodgkin's lymphoma undergoing autologous bone marrow transplantation. Blood 83:2823, 1994
23. Ponchio L, Beguin Y, Farina G, Pedrazzoli P, Pedrotti C, Poggi G, Rosti V, Bergamaschi G, Battistel V, Cazzola M: Evaluation of erythroid marrow response to recombinant human erythropoietin in patients with cancer anaemia. Haematologica 77:494, 1992
24. Miller CB, Platanias LC, Mills SR, Zahurak ML, Ratain MJ, Ettinger DS, Jones RJ: Phase I-II trial of erythropoietin in the treatment of cisplatin-associated anemia. J Natl Cancer Inst 84:98, 1992
25. Ludwig H, Fritz E, Leitgeb C, Krainer M, Kührer I, Sagaster P, Umek H: Erythropoietin treatment for chronic anemia of selected hematological malignancies and solid tumors. Ann Oncol 4:161, 1993
26. Huinink WW, van Tinteren H, Valkenet L, Dalesio O, Ehmer B: Treatment of platinum induced anemia in ovarian cancer patients: A controlled study with erythropoietin to prevent anemia and blood transfusions. Ann Oncol 5:89, 1994 (suppl, abstr)
27. Rose E, Rai K, Revicki D, Brown R, Reblando J: Clinical and health status assessments in anemic chronic lymphocytic leukemia (CLL) patients treated with epoetin alfa (EPO). Blood 8:526, 1994 (suppl, abstr)
28. Klaesson S, Ringdén O, Ljungman P, Lönnqvist B, Wennberg L: Reduced blood transfusions requirements after allogeneic bone marrow transplantation: Results of a randomised, double-blind study with high-dose erythropoietin. Bone Marrow Transplant 13:397, 1994
29. Evans RW, Rader B, Manninen DL, and the Cooperative Multicenter EPO Clinical Trial Group: The quality of life of hemodialysis recipient treated with recombinant human erythropoietin. JAMA 263:825, 1990
30. Leitgeb C, Pecherstorfer M, Fritz E, Ludwig H: Quality of life in chronic anemia of cancer during treatment with recombinant human erythropoietin. Cancer 73:2535, 1994
31. Ludwig H, Fritz E, Leitgeb C, Pecherstorfer M, Samonigg H, Schuster J: Prediction of response to erythropoietin treatment in chronic anemia of cancer. Blood 84:1056, 1994